Brittany L. Gardner
Brittany L. Gardner has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Amal Ahmed
Meharry Medical College School of Medicine Nashville Tennessee USA
13 shared publications - Avery D. Posey
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
13 shared publications - Emma E. Furth
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
13 shared publications - Fang Liu
University of Pennsylvania 1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine Philadelphia, Pennsylvania
13 shared publications - Hyeon-Gyu S. Lewis
University of Pennsylvania 3 Philadelphia, Pennsylvania
13 shared publications - John T. Keane
UNIVERSITY OF PENNSYLVANIA 2
13 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Tumors remodel the extracellular matrix (ECM) and glycosylation, yielding epitopes with restricted or limited detectability in normal adult tissues. In this study, we evaluated the O-glycosylated type III connecting segment domain of fibronectin (Tn-FN) as a chimeric antigen receptor (CAR) T-cell target. FDC6-BBζ CAR T cells recognizing Tn-FN were benchmarked against extra domain B-FN–targeted L19-BBζ and Tn-MUC1–targeted 5E5-BBζ. FDC6-BBζ mediated robust, antigen-dependent activation and cytotoxicity, outperforming L19-BBζ and matching 5E5-BBζ in vitro and in NOD/SCID gamma xenografts of prostate cancer. FDC6-BBζ and 5E5-BBζ CAR T cells achieved durable tumor control with increased intratumoral CD3+ infiltration and reduced tumor–collagen overlap. Cytotoxicity required an intact tumor IFNγ receptor 1 (IFNγR1); L19-BBζ further depended on Fas, whereas FDC6-BBζ and 5E5-BBζ were less Fas-dependent. Tumoral Toll-like receptor (TLR) 2/6 or TLR4 agonism restored FDC6-BBζ killing of IFNγR1-deficient targets and induced broad inflammatory and stress–response programs. Pharmacologic perturbation implicated caspase-dependent mechanisms and a contribution from inflammasome-linked signaling, whereas ferroptosis blockade did not abrogate restored killing. These findings establish Tn-FN as a glycoform-restricted, ECM-derived CAR target and show that innate agonists can reprogram tumor state to overcome resistance from impaired IFNγ signaling.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Tumors remodel the extracellular matrix (ECM) and glycosylation, yielding epitopes with restricted or limited detectability in normal adult tissues. In this study, we evaluated the O-glycosylated type III connecting segment domain of fibronectin (Tn-FN) as a chimeric antigen receptor (CAR) T-cell target. FDC6-BBζ CAR T cells recognizing Tn-FN were benchmarked against extra domain B-FN–targeted L19-BBζ and Tn-MUC1–targeted 5E5-BBζ. FDC6-BBζ mediated robust, antigen-dependent activation and cytotoxicity, outperforming L19-BBζ and matching 5E5-BBζ in vitro and in NOD/SCID gamma xenografts of prostate cancer. FDC6-BBζ and 5E5-BBζ CAR T cells achieved durable tumor control with increased intratumoral CD3+ infiltration and reduced tumor–collagen overlap. Cytotoxicity required an intact tumor IFNγ receptor 1 (IFNγR1); L19-BBζ further depended on Fas, whereas FDC6-BBζ and 5E5-BBζ were less Fas-dependent. Tumoral Toll-like receptor (TLR) 2/6 or TLR4 agonism restored FDC6-BBζ killing of IFNγR1-deficient targets and induced broad inflammatory and stress–response programs. Pharmacologic perturbation implicated caspase-dependent mechanisms and a contribution from inflammasome-linked signaling, whereas ferroptosis blockade did not abrogate restored killing. These findings establish Tn-FN as a glycoform-restricted, ECM-derived CAR target and show that innate agonists can reprogram tumor state to overcome resistance from impaired IFNγ signaling.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Generation and validation of PC3-Fas-KO and PC3-IFNgR1-KO clones.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Generation and validation of PC3-Fas-KO and PC3-IFNgR1-KO clones.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Body weight and representative normal-organ histology after CAR T cell treatment.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Body weight and representative normal-organ histology after CAR T cell treatment.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Relative staining of CAR target antigens on PC3-WT cells.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Relative staining of CAR target antigens on PC3-WT cells.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
FDC6-BBz CAR T cells mediate cytotoxicity against DU145 prostate cancer cells, and LPS enhances killing of DU145-2B11 targets.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
FDC6-BBz CAR T cells mediate cytotoxicity against DU145 prostate cancer cells, and LPS enhances killing of DU145-2B11 targets.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Validation of PC3-IIICS-FN-KO and PC3-GALNT6-KO lines and associated transcriptional and in vivo phenotypes.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Validation of PC3-IIICS-FN-KO and PC3-GALNT6-KO lines and associated transcriptional and in vivo phenotypes.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S4 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of 5E5-BBz T cells against GFP+ PC3 targets.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S4 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of 5E5-BBz T cells against GFP+ PC3 targets.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of FDC6-BBz T cells against GFP+ PC3 targets.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of FDC6-BBz T cells against GFP+ PC3 targets.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of NTD T cells against GFP+ PC3 targets.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of NTD T cells against GFP+ PC3 targets.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S3 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of L19-BBz T cells against GFP+ PC3 targets.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S3 from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Real-time cytotoxicity of L19-BBz T cells against GFP+ PC3 targets.